ProQR Therapeutics
PRQR
25 hedge funds and large institutions have $32.9M invested in ProQR Therapeutics in 2018 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 4 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 6
2.57% less ownership
Funds ownership: 36.12% → 33.55% (-2.6%)
7% less funds holding
Funds holding: 27 → 25 (-2)
11% less capital invested
Capital invested by funds: $37.1M → $32.9M (-$4.24M)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.61M |
| 2 |
Jennison Associates
New York
|
+$1.01M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$413K |
| 4 |
FSA
Franklin Street Advisors
Chapel Hill,
North Carolina
|
+$193K |
| 5 |
Morgan Stanley
New York
|
+$169K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$5.03M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$563K |
| 3 |
OPPM
Opus Point Partners Management
New York
|
-$495K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$45K |
| 5 |
WS
Wedbush Securities
Los Angeles,
California
|
-$35K |
PRQR Hedge Fund Activity: Q1 2018 in Review
25 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q1 2018, worth a combined $32.9M — down 11% from $37.1M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of PRQR and 2 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 8 added.
The largest buyer was Adage Capital Partners, adding an estimated $1.61M. The largest seller was Redmile Group, exiting entirely with an estimated $5.03M sold.
- 25 institutional investors held ProQR Therapeutics (PRQR) as of Q1 2018, down from 27 in Q4 2017.
- Funds reported $32.9M of ProQR Therapeutics stock for Q1 2018, down 11% quarter-over-quarter.
- 2 funds opened new ProQR Therapeutics positions in Q1 2018 and 4 closed out, a net change of -2 holders.
- The largest ProQR Therapeutics buyer in Q1 2018 was Adage Capital Partners, an estimated $1.61M added.
- The largest ProQR Therapeutics seller in Q1 2018 was Redmile Group, an estimated $5.03M sold.
Based on aggregated 13F filings for Q1 2018.